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Abstract A straightforward and efficient preparation of 5-
membered cyclic guanidines bearing an ester, a hydroxymethyl or a 
Weinreb amide functional group at C-4 is described from L-serine. 
The novel synthetic route provides cyclic guanidines in which the 
three nitrogen atoms are orthogonally protected making them 
highly suitable for further transformations into natural products or 
their analogues via the introduced functional groups. 
Key words cyclic guanidine, amino acid, azide, orthogonal 
protection, Weinreb amide 
 
The cyclic guanidine motif is present in a wide range of 
naturally-occurring compounds,1 notably as a structural unit of 
non-proteinogenic amino acids, examples of which are 
enduracididine (1),2 its 3-hydroxy derivatives (2),3 
capreomycidine4 (3) and tetrahydrolathyrin5 (4) or of alkaloids 
such as trachycladindole B6 (5) and its derivatives (Figure 1). 
These amino acids have been isolated either in their free form 
or as components of cyclic peptides. Thus, compound 1 is a 
structural unit of the cyclopeptide enduracidin2 and of the 
recently described teixobactin,7 compound 2 of the 
mannopeptimycins3 and compound 3 of capreomycins and 
tuberactinomycins,8 all of which display antibiotic or antifungal 
action. In terms of synthesis, formation of the cyclic guanidine 
unit usually depends on the generation of a 1,2- or 1,3-diamino 
motif which classically can then be cyclized using cyanogen 
bromide, an inexpensive but highly toxic reagent. Alternatively, 
one of the amino groups can be coupled to a reactive isothiourea 
derivative which then undergoes cyclization upon heating.9 
Starting from a 1-hydroxyl-2-(or 3-)-guanidine unit, a 
Mitsunobu-type cyclodehydration has also been used to prepare 
a 5-(or 6-) membered cyclic guanidine. 10-12 
We ourselves have recently described the syntheses of both L-
enduracididine (1)13 and tetrahydrolathyrin (4)14 by way of 
prior iminoiodane-mediated aziridination of a common, easily 
accessible starting material, L-allylglycine. Subsequent 
nucleophilic opening of the aziridine by azide (for 
enduracididine) or nitrile (for tetrahydrolathyrin) provided the 
required diamino precursors after reduction. The lack of 
diasteoselectivity in the aziridination step was, however, a 
complicating factor in both cases. 
 
Figure 1 Examples of natural products containing a C-4 substituted 
cyclic guanidine structural unit 
It occurred to us that a more convergent way of synthesizing 
cyclic guanidine-containing compounds, be they natural 
products, analogues thereof or in the context of drug discovery, 
would consist of preparing a pre-formed cyclic guanidine 
moiety bearing a functional group which could thereafter be 
used to link another molecule (e.g., an amino acid, an indole...). 
Such a tactic was recently described by us whereby halogenated 
cyclic guanidines were obtained in one step by halocyclization 
of unsaturated guanidines using a combination of lithium 
halides and Koser’s reagent.15 We now report herein the 
efficient preparation, starting from L-serine, of 5-membered 
cyclic guanidines functionalized at C-4 with an ester, a Weinreb 
amide or a hydroxymethyl group and in which, moreover, the 
three guanidine nitrogen atoms are orthogonally protected. The 
possibility of accessing a mono-N-deprotected cyclic guanidine 
could be highly valuable, for example, for the introduction of 
different substituents on each nitrogen atom in the context of a 
structure-activity relationship study of a particular bio-active 
molecule. 
Diego R. C. Silva,a,b 
Edmilson J. Maria,b 
Rosa M. Suárez Ordóñez,a 
Josiane Thierry,a 
Kevin Cariou,*a 
Robert H. Dodd*a 
 
a Institut de Chimie des Substances Naturelles, 
CNRS UPR 2301, Univ. Paris-Sud, Univ. Paris-
Saclay, 1 Avenue de la Terrasse, 91198 Gif-sur-
Yvette, France 
b Universidade Estadual do Norte Fluminense 
Darcy Ribeiro, Campos dos Goytacazes, RJ, Brazil 
* Kevin.cariou@cnrs.fr, * Robert.dodd@cnrs.fr 
Click here to insert a dedication. 
  
Synlett Letter / Cluster / New Tools 
Template for SYNLETT © Thieme  Stuttgart · New York 2016-12-16 page 2 of 4 
The success of our methodology was very much dependent on 
the judicious choice of nitrogen atom protecting groups.16 
Indeed, a frequently encountered problem in working with 
partially N-protected cyclic guanidines is scrambling of the 
protecting group(s)17 making characterization and purification 
of products difficult and lowering yields. For our initial studies 
starting from L-serine methyl ester (6), we thus chose to protect 
the amine function with a p-methoxybenzyl (PMB) group not 
prone to migration but easily removed under mild oxidizing 
conditions (Scheme 1). Additionally, the electron-rich nature of 
the group should assist in the subsequent cyclization step. Thus, 
reaction of 6 with p-methoxybenzaldehyde (7) in methanol in 
the presence of triethylamine followed by sodium borohydride-
promoted reduction of the resulting intermediate imine 
provided the desired N-PMB serine methyl ester 8 in 81% 
overall yield. Compound 8 in dichloromethane was then treated 
at -78 °C with thionyl chloride in the presence of pyridine to 
give the oxathiazolidine derivative 9. The latter was oxidized to 
the cyclic sulfamidate 10 in 77% overall yield using catalytic 
ruthenium trichloride and sodium metaperiodate in 
acetonitrile.18 Regioselective ring-opening of compound 10 in 
acetone was very efficiently achieved by the action of aqueous 
sodium azide (Warning !) at room temperature, furnishing 
methyl (2S)-3-azido-2-(p-methoxybenzyl)aminopropanoate 11 
in 85% yield. 19 
 
Scheme 1 Preparation of the 2-amino-3-azido precursors for cyclic 
guanidine formation 
Transformation of azido derivative 11 into the orthogonally N-
protected cyclic guanidine 4-carboxylic ester 16 is depicted in 
Scheme 2. Thus, the azido function of 11 was first reduced to the 
primary amine 12 via a Staudinger reaction using 
triphenylphosphine in aqueous dichloromethane. This amine 
was not purified but was reacted directly with 1,3-
bis(benzyloxycarbonyl)-2-methylisothiourea (13) in the 
presence of triethylamine in dichloromethane.20 The resulting 
guanidino derivative 14, obtained in 95% overall yield for both 
steps, underwent cyclization when heated for 2 days at 70 °C in 
acetonitrile, providing a 75% yield of methyl 2-
iminoimidazolidine-4-carboxylate 15.21 Finally, treatment of 
compound 15 with excess Boc anhydride and DMAP in 
acetonitrile led to the targeted fully N-protected, C-4 
functionalized cyclic guanidine 16 in 73% yield. The latter could 
furthermore be transformed in 90% yield to the C-4 
hydroxymethyl derivative 17 by reduction of the ester with 
lithium borohydride in ethanol at 0 °C. The orthogonality of our 
design was illustrated by the selective deprotection of the Cbz of 
16 to give 18 by hydrogenolysis. Thus it is possible to go from 
2,3 diprotected guanidine (15) to tri-protected (16), to 1,3 
diprotected guanidine (18). 
 
Scheme 2 Preparation of the C-4 functionalized, N-protected 5-
membered cyclic guanidines 
For the preparation of the Weinreb amide analogue of the cyclic 
guanidine ester 16, the corresponding amide of L-serine (i.e., 
compound 21) was first synthesized as shown in Scheme 3. This 
two-step procedure consisted of EDCI-promoted coupling of 
commercial N-Boc-L-serine (19) with N,O-
dimethylhydroxylamine in the presence of N-methylmorpholine 
(NMM) to give amide 20. Removal of the N-Boc protecting group 
using trifluoroacetic acid in dichloromethane then provided 21 
in 72% overall yield.  
 
Scheme 3 Preparation of the Weinreb amide of L-serine 
Application to 21 of the same reaction sequence used for the 
preparation of cyclic guanidine 16 from L-serine methyl ester 
(6) then allowed efficient access to optically pure, N-protected 
cyclic guanidine derivative 29 having now a Weinreb amide at 
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the C-4 position suitable for further transformations (Schemes 1 
and 2).20,21  
In conclusion, esters 15, 16 or 18 primary alcohol 17 and 
Weinreb amide 29 represent five functionalized and 
stereochemically defined cyclic guanidine derivatives which can 
serve as starting materials for the synthesis of a variety of 
natural products containing this 5-membered heterocyclic unit. 
An added feature of the synthetic strategy presented here is that 
these key compounds can be obtained with each nitrogen atom 
of the guanidine unit being orthogonally protected allowing 
their selective deprotection and substitution in the context of a 
structure-activity study (e.g., N-alkylation as in the 
trachycladindoles 5) or of total synthesis (e.g., the 
mannopeptimycins).10b Such transformations are the object of 
our ongoing studies. 
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(75 MHz, CDCl3): δ 173.4 (C), 163.8 (C), 159.0 (C), 156.2 (C), 153.7 
(C), 136.9 (C), 134.9 (C), 131.4 (C), 129.8 (2 CH, PMB), 129.0 (CH, 
Cbz), 128.9 (CH, Cbz), 128.8 (CH, Cbz), 128.6 (CH, Cbz), 128.4 (CH, 
Cbz), 128.1 (CH, Cbz), 114.0 (2 CH, PMB), 68.4 (CH2, Cbz), 67.3 
(CH2, Cbz), 58.8 (CH-N), 55.5 (CH3, MeO), 52.5 (CH3, MeO), 51.4 
(CH2), 42.8 (CH2). HRMS m/z calcd for C29H33N4O7 [M+H]+: 
549.2344; found: 549.2329. 
N-Methoxy-N-methyl (2S)-3-(2,3-bis(benzyloxycarbonyl)-
guanidino)-2-(p-methoxybenzylamino)propanamide (27): 
Treatment of amine 25 (0.7 mmol) as described above provided, 
after flash chromatography of the crude product on silica gel 
(EtOAc/heptane, 6:4), compound 26 as a yellow oil (87% yield 
from 24). [α]D20 - 15.27 (c = 1.12, CHCl3); IR (neat, cm-1): νmax 
3330, 2931, 1732, 1638, 1563, 1512, 1245, 1204, 1052, 803, 746, 
697; 1H NMR (300 MHz, CDCl3): δ 11.6 (br s, 1H, NH), 8.85, (br s, 
1H, NH), 7.40-7.24 (m, 10H, CH, Cbz) 7.28 (d, J = 8.6 Hz, 2H, CH, 
PMB), 6.78 (d, J = 8.6 Hz, 2H, CH, PMB), 5.24 (d, J = 12.2 Hz, 1H, 
CH2, Cbz), 5.18 (d, J = 12.2 Hz, 1H, CH2, Cbz), 5.10 (d, J = 12.4 Hz, 
1H, CH2), 5.05 (d, J = 12.4 Hz, 1H, CH2), 3.89-3.81 (m, 1H, CH2), 
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3.79 (d, J = 13.0 Hz, 1H, CH2, PMB), 3.75 (s, 3H, MeO), 3.74-3.70 
(m, 1H, CH), 3.54 (s, 3H, MeO), 3.51 (d, J = 12.8 Hz, 1H, CH2, PMB), 
3.15 (s, 3H, MeN), 3.20-3.10 (m, 1H, CH2), 1.96 (br s, 1H, NH); 13C 
NMR (75 MHz, CDCl3): δ 163.8 (C), 158.9 (C), 156.1 (C), 153.7 (C), 
137.0 (C), 135.0 (C), 131.8 (C), 130.4 (2 CH, PMB), 128.9 (CH, Cbz), 
128.9 (CH, Cbz), 128.8 (CH, Cbz), 128.6 (CH, Cbz), 128.3 (CH Cbz), 
128.1 (CH Cbz), 113.9 (2 CH PMB), 68.3 (CH2, Cbz), 67.2 (CH2, 
Cbz), 61.8 (CH3 MeO), 55.7 (CH-N), 55.5 (CH3, MeO), 51.4 (CH2), 
43.3 (CH2), 32.5 (CH3, MeN). HRMS m/z calcd for C30H36N5O7 
[M+H]+: 578.2609; found: 578.2618. 
(21) Methyl (4S)-2-(benzyloxycarbonylimino)-3-(p-methoxy-
benzyl)-imidazoledine-4-carboxylate (15): A solution of 
compound 14 (2.56 g, 4.6 mmol) in acetonitrile (25 mL) was 
heated at 70 °C for 2 d. The reaction mixture was then cooled to 
room temperature, the solvent was removed under vacuum and 
the residue was purified by flash column chromatography on 
silica gel (EtOAc/heptane, 1:1) to provide the cyclic guanidine 15 
as a colorless oil (1.39 g, 75%). [α]D20 + 25.67 (c = 0.9, CHCl3); IR 
(neat, cm-1): νmax 3374, 2926, 1646, 1587, 1513, 1248, 1128, 
1095, 799; 1H NMR (300 MHz, CDCl3): δ 7.95, (br s, 1H, NH), 7.37 
(d, J = 6.8 Hz, 2H, Cbz), 7.31-7.21 (m, 3H, Cbz), 7.10 (d, J = 8.6 Hz, 
2H, CH, PMB), 6.78 (d, J = 8.6 Hz, 2H, CH PMB), 5.16-5.05 (m, 3H), 
4.10-4.03 (m, 2H,), 3.99 (dd, J = 10.0, 6.0 Hz, 1H, CH2), 3.73 (s, 3H, 
MeO), 3.67 (s, 3H, MeO), 3.63 (dd, J = 10.0, 6.0 Hz, 1H, CH2); 13C 
NMR (75 MHz, CDCl3): δ 170.4 (C), 164.4 (C), 163.5 (C), 159.3 (C), 
137.3 (C), 130.0 (2 CH, PMB), 128.3 (2 CH, Cbz), 128.2 (2 CH, Cbz), 
127.7 (CH, Cbz), 114.1 (2 CH, PMB), 67.0 (CH2, Cbz), 56.4 (CH-N), 
55.3 (CH3, MeO), 52.7 (CH3, MeO), 46.2 (CH2), 44.5 (CH2). HRMS 
m/z calcd for C21H24N3O5 [M+H]+: 398.1710; found: 398.1711. 
N-Methoxy-N-methyl (4S)-2-(benzyloxycarbonylimino)-3-(p-
methoxybenzyl)imidazolidine-4-carboxamide (28). Treatment 
of  compound 26 (0.6 mmol) as described above provided, after 
flash column chromatography of the crude product on silica gel 
(EtOAc/heptane, 8:2), compound 27 as a colorless oil (74%). [α]D20 
+ 27.39 (c = 0.92, CHCl3); IR (neat, cm-1): νmax 3374, 2926, 1646, 
1587, 1513, 1248, 1128, 1095, 799; 1H NMR (300 MHz, CDCl3): δ 
7.94, (br s, 1H, NH), 7.43-7.24 (m, 5H, CH, Cbz), 7.26 (d, J = 8.5 Hz, 
2H, CH, PMB), 6.81 (d, J = 8.5 Hz, 2H, CH, PMB), 5.23 (d, J = 14.7 Hz, 
1H, CH2), 5.16 (d, J = 12.4, 2H, CH2), 5.10 (d, J = 12.4, 2H, CH2), 4.27 
(dd, J = 10.6 Hz, 6.5 Hz, 1H, CH), 3.98 (d, J = 14.7, 1H, CH2), 3.81-3.73 
(m, 1H, CH2), 3.76 (s, 3H, MeO), 3.46 (dd, J = 9.6 Hz, 6.6 Hz, 1H, CH2), 
3.35 (s, 3H, MeO), 3.14 (s, 3H, MeN); 13C NMR (75 MHz, CDCl3): δ 
169.9 (C), 164.6 (C), 164.2 (C), 159.4 (C), 137.6 (C), 130.4 (2 CH, 
PMB), 128.5 (CH, Cbz), 128.3 (CH, Cbz), 127.8 (CH, Cbz), 114.2 (2 CH, 
PMB), 67.1 (CH2, Cbz), 61.4 (CH3, MeO), 55.5 (CH3, MeO), 55.0 (CH-
N), 45.9 (CH2), 44.6 (CH2), 29.9 (CH3, MeN). HRMS m/z calcd for 
C22H27N4O5 [M+H]+: 427.1976; found: 427.1984. 
 
 
 
 
 
 
 
 
